Literature DB >> 33551175

Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.

Mythili P Pathipati1, Thomas K Yohannan2, Lu Tian3, Kathleen Hornbacker4, Jalen A Benson5, Gerald J Berry6, Natalie S Lui5, Pamela L Kunz7, Sukhmani K Padda8.   

Abstract

BACKGROUND: Well-differentiated lung neuroendocrine tumors (NETs), also known as typical and atypical carcinoids, have a decreased incidence of lymph node (LN) and distant metastases compared to poorly differentiated lung NETs. We aimed to (i) examine the clinicopathologic features associated with LN involvement in lung carcinoids and (ii) describe the postoperative management of patients with LN metastases.
METHODS: We identified 98 patients who underwent surgical resection and lymph node sampling at Stanford University. We assessed the following and used AJCC staging version 7: clinical features (age, sex, race, prior malignancy, smoking history), tumor features (functional syndrome, histology, size, location, laterality), pre-operative workup performed (imaging and suspicion of LN metastases), surgery (nodes and stations sampled, margin status, surgical approach, and type of surgery), and recurrence outcome. These features were examined between patients with and without LN metastases using the Wilcoxon test (continuous variables) and Fisher's exact test (categorical variables).
RESULTS: 87 patients (89%) had typical carcinoid and 11 patients (11%) had atypical carcinoid. 17 patients were found to have at least one positive lymph node, with 11 having N1 disease and 6 having N2 disease. In the univariable analysis, patients with lymph node disease were more likely to have recurrence of lung carcinoid (29% vs. 6%, p=0.01). In the multivariable logistic regression, there was a trend towards performance of preoperative SSTR imaging and lymph node involvement (OR = 3.06, p=0.07). No patients received adjuvant therapy.
CONCLUSION: We found a trend for the performance of SSTR imaging and association of lymph node metastases in both univariable and multivariable analysis. A large proportion (41%) of patients with lymph node positive disease had < 2 cm tumors. This suggests the potential importance of incorporating SSTR imaging into routine practice and not restricting the use of this staging modality in patients with small tumors.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lung cancer; Lung carcinoids; Lymph node metastases; Neuroendocrine tumors; Somatostatin-receptor (SSTR) imaging

Mesh:

Year:  2021        PMID: 33551175      PMCID: PMC8026717          DOI: 10.1016/j.lungcan.2021.01.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  26 in total

1.  68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Authors:  Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 2.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Authors:  M E Caplin; E Baudin; P Ferolla; P Filosso; M Garcia-Yuste; E Lim; K Oberg; G Pelosi; A Perren; R E Rossi; W D Travis
Journal:  Ann Oncol       Date:  2015-02-02       Impact factor: 32.976

3.  Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients.

Authors:  Federico Rea; Giovanna Rizzardi; Andrea Zuin; Giuseppe Marulli; Samuele Nicotra; Renato Bulf; Marco Schiavon; Francesco Sartori
Journal:  Eur J Cardiothorac Surg       Date:  2006-11-30       Impact factor: 4.191

4.  Natural history of typical pulmonary carcinoid tumors: a comparison of nonsurgical and surgical treatment.

Authors:  Dan J Raz; Rebecca A Nelson; Frederic W Grannis; Jae Y Kim
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

5.  Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Ann Thorac Surg       Date:  2014-12-10       Impact factor: 4.330

6.  Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).

Authors:  D R Albanus; J Apitzsch; Z Erdem; O Erdem; F A Verburg; F F Behrendt; F M Mottaghy; A Heinzel
Journal:  Eur J Radiol       Date:  2015-06-29       Impact factor: 3.528

7.  Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.

Authors:  Amit Tirosh; Georgios Z Papadakis; Corina Millo; Dima Hammoud; Samira M Sadowski; Peter Herscovitch; Karel Pacak; Stephen J Marx; Lily Yang; Pavel Nockel; Jasmine Shell; Patience Green; Xavier M Keutgen; Dhaval Patel; Naris Nilubol; Electron Kebebew
Journal:  Gastroenterology       Date:  2017-11-16       Impact factor: 22.682

8.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Authors:  James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

9.  NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Authors:  Manisha H Shah; Whitney S Goldner; Thorvardur R Halfdanarson; Emily Bergsland; Jordan D Berlin; Daniel Halperin; Jennifer Chan; Matthew H Kulke; Al B Benson; Lawrence S Blaszkowsky; Jennifer Eads; Paul F Engstrom; Paul Fanta; Thomas Giordano; Jin He; Martin J Heslin; Gregory P Kalemkerian; Fouad Kandeel; Sajid A Khan; Wajih Zaheer Kidwai; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Craig A Sussman; Nikolaos A Trikalinos; Nataliya A Uboha; Jonathan Whisenant; Terence Wong; James C Yao; Jennifer L Burns; Ndiya Ogba; Griselda Zuccarino-Catania
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 11.908

Review 10.  Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.

Authors:  Rohit Gosain; Sarbajit Mukherjee; Sai S Yendamuri; Renuka Iyer
Journal:  Cancers (Basel)       Date:  2018-12-12       Impact factor: 6.639

View more
  1 in total

1.  Optimal Cut-Off Values of the Positive Lymph Node Ratio and the Number of Removed Nodes for Patients Receiving Resection of Bronchopulmonary Carcinoids: A Propensity Score-Weighted Analysis of the SEER Database.

Authors:  Qichen Chen; Mingxia Li; Pan Wang; Jinghua Chen; Hong Zhao; Jun Zhao
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.